The vesicular monoamine transporter is not regulated by dopaminergic drug treatments
- 1 December 1995
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 294 (2-3), 577-583
- https://doi.org/10.1016/0014-2999(95)00594-3
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's diseaseAnnals of Neurology, 1993
- In vivo imaging of monoaminergic nerve terminals in normal and MPTP‐lesioned primate brain using positron emission tomography (PET) and [11C]tetrabenazineSynapse, 1993
- In vivo binding of [11C]tetrabenazine to vesicular monoamine transporters in mouse brainLife Sciences, 1992
- Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugsPsychopharmacology, 1990
- Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brainSynapse, 1990
- Modification of vesicular dopamine and norepinephrine by mono amine oxidase inhibitorsBiochemical Pharmacology, 1989
- Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserinNeuroscience, 1989
- In vivoevaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomographyActa Neurologica Scandinavica, 1987
- L-Dopa Methyl Ester—A Candidate for Chronic Systemic Delivery of L-Dopa in Parkinsonʼs DiseaseClinical Neuropharmacology, 1984
- Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in BrainScience, 1977